Danny Schuring
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Danny Schuring has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Frank J. Lagerwaard
Department of Radiation Oncology, VU Medical Center, Amsterdam, The Netherlands
3 shared publications - Joachim Widder
Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, General Hospital of Vienna, Vienna, Austria
3 shared publications - Suresh Senan
Department of Radiation Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1117 Amsterdam, The Netherlands
3 shared publications - Coen W. Hurkmans
Department of Radiation Oncology, Catharina Hospital, Eindhoven, Netherlands
2 shared publications - Gert Johan Meijer
Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
2 shared publications Johan P. Cuijpers
2 shared publications
Latest Publications
- Open Access
- 31 January 2013
- Published by Springer Nature in Radiation Oncology
- Vol. 8 (1) , 26
Multi-institutional comparison of volumetric modulated arc therapy vs. intensity-modulated radiation therapy for head-and-neck cancer: a planning study
Background: Compared to static beam Intensity-Modulated Radiation Therapy (IMRT), the main advantage of Volumetric Modulated Arc Therapy (VMAT) is a shortened delivery time, which leads to improved patient comfort and possibly smaller intra-fraction movements. This study aims at a treatment planner-independent comparison of radiotherapy treatment planning of IMRT and VMAT for head-and-neck cancer performed by several institutes and based on the same CT- and contouring data. Methods: Five institutes generated IMRT and VMAT plans for five oropharyngeal cancer patients using either Pinnacle3 or Oncentra Masterplan to be delivered on Elekta linear accelerators. Results: Comparison of VMAT and IMRT plans within the same patient and institute showed significantly better sparing for almost all OARs with VMAT. The average mean dose to the parotid glands and oral cavity was reduced from 27.2 Gy and 39.4 Gy for IMRT to 25.0 Gy and 36.7 Gy for VMAT, respectively. The dose conformity at 95% of the prescribed dose for PTVboost and PTVtotal was 1.45 and 1.62 for IMRT and 1.37 and 1.50 for VMAT, respectively. The average effective delivery time was reduced from 13:15 min for IMRT to 5:54 min for VMAT. Conclusions: Independently of institution-specific optimization strategies, the quality of the VMAT plans including double arcs was superior to step-and-shoot IMRT plans including 5–9 beam ports, while the effective treatment delivery time was shortened by ~50% with VMAT.
- 31 January 2013
- Published by Springer Nature in Radiation Oncology
- Vol. 8 (1) , 26
Open AccessMulti-institutional comparison of volumetric modulated arc therapy vs. intensity-modulated radiation therapy for head-and-neck cancer: a planning study
Background: Compared to static beam Intensity-Modulated Radiation Therapy (IMRT), the main advantage of Volumetric Modulated Arc Therapy (VMAT) is a shortened delivery time, which leads to improved patient comfort and possibly smaller intra-fraction movements. This study aims at a treatment planner-independent comparison of radiotherapy treatment planning of IMRT and VMAT for head-and-neck cancer performed by several institutes and based on the same CT- and contouring data. Methods: Five institutes generated IMRT and VMAT plans for five oropharyngeal cancer patients using either Pinnacle3 or Oncentra Masterplan to be delivered on Elekta linear accelerators. Results: Comparison of VMAT and IMRT plans within the same patient and institute showed significantly better sparing for almost all OARs with VMAT. The average mean dose to the parotid glands and oral cavity was reduced from 27.2 Gy and 39.4 Gy for IMRT to 25.0 Gy and 36.7 Gy for VMAT, respectively. The dose conformity at 95% of the prescribed dose for PTVboost and PTVtotal was 1.45 and 1.62 for IMRT and 1.37 and 1.50 for VMAT, respectively. The average effective delivery time was reduced from 13:15 min for IMRT to 5:54 min for VMAT. Conclusions: Independently of institution-specific optimization strategies, the quality of the VMAT plans including double arcs was superior to step-and-shoot IMRT plans including 5–9 beam ports, while the effective treatment delivery time was shortened by ~50% with VMAT.
- 1 November 2012
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 105 (2) , 174-179
High precision bladder cancer irradiation by integrating a library planning procedure of 6 prospectively generated SIB IMRT plans with image guidance using lipiodol markers
- 1 November 2012
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 105 (2) , 174-179
High precision bladder cancer irradiation by integrating a library planning procedure of 6 prospectively generated SIB IMRT plans with image guidance using lipiodol markers
- 1 September 2011
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 100 (3) , 396-401
Dose painting by contours versus dose painting by numbers for stage II/III lung cancer: Practical implications of using a broad or sharp brush
- 1 September 2011
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 100 (3) , 396-401
Dose painting by contours versus dose painting by numbers for stage II/III lung cancer: Practical implications of using a broad or sharp brush
- 1 July 2011
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 80 (3) , 918-927
Quality Assurance of 4D-CT Scan Techniques in Multicenter Phase III Trial of Surgery Versus Stereotactic Radiotherapy (Radiosurgery or Surgery for Operable Early Stage (Stage 1A) Non–Small-Cell Lung Cancer [ROSEL] Study)
- 1 July 2011
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 80 (3) , 918-927
Quality Assurance of 4D-CT Scan Techniques in Multicenter Phase III Trial of Surgery Versus Stereotactic Radiotherapy (Radiosurgery or Surgery for Operable Early Stage (Stage 1A) Non–Small-Cell Lung Cancer [ROSEL] Study)
- 1 September 2009
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 75 (1) , 318
In Reply to Dr. Xiao et al.
- 1 September 2009
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 75 (1) , 318
In Reply to Dr. Xiao et al.
- Open Access
- 12 January 2009
- Published by Springer Nature in Radiation Oncology
- Vol. 4 (1) , 1
Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study
A phase III multi-centre randomised trial (ROSEL) has been initiated to establish the role of stereotactic radiotherapy in patients with operable stage IA lung cancer. Due to rapid changes in radiotherapy technology and evolving techniques for image-guided delivery, guidelines had to be developed in order to ensure uniformity in implementation of stereotactic radiotherapy in this multi-centre study.
- 12 January 2009
- Published by Springer Nature in Radiation Oncology
- Vol. 4 (1) , 1
Open AccessRecommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study
A phase III multi-centre randomised trial (ROSEL) has been initiated to establish the role of stereotactic radiotherapy in patients with operable stage IA lung cancer. Due to rapid changes in radiotherapy technology and evolving techniques for image-guided delivery, guidelines had to be developed in order to ensure uniformity in implementation of stereotactic radiotherapy in this multi-centre study.
- Open Access
- 28 July 2008
- Published by Springer Nature in Radiation Oncology
- Vol. 3 (1) , 21
Developing and evaluating stereotactic lung RT trials: what we should know about the influence of inhomogeneity corrections on dose
To investigate the influence of inhomogeneity corrections on stereotactic treatment plans for non-small cell lung cancer and determine the dose delivered to the PTV and OARs. For 26 patients with stage-I NSCLC treatment plans were optimized with unit density (UD), an equivalent pathlength algorithm (EPL), and a collapsed-cone (CC) algorithm, prescribing 60 Gy to the PTV. After optimization the first two plans were recalculated with the more accurate CC algorithm. Dose parameters were compared for the three different optimized plans. Dose to the target and OARs was evaluated for the recalculated plans and compared with the planned values. For the CC algorithm dose constraints for the ratio of the 50% isodose volume and the PTV, and the V20 Gy are harder to fulfill. After recalculation of the UD and EPL plans large variations in the dose to the PTV were observed. For the unit density plans, the dose to the PTV varied from 42.1 to 63.4 Gy for individual patients. The EPL plans all overestimated the PTV dose (average 48.0 Gy). For the lungs, the recalculated V20 Gy was highly correlated to the planned value, and was 12% higher for the UD plans (R2 = 0.99), and 15% lower for the EPL plans (R2 = 0.96). Inhomogeneity corrections have a large influence on the dose delivered to the PTV and OARs for SBRT of lung tumors. A simple rescaling of the dose to the PTV is not possible, implicating that accurate dose calculations are necessary for these treatment plans in order to prevent large discrepancies between planned and actually delivered doses to individual patients.
- 28 July 2008
- Published by Springer Nature in Radiation Oncology
- Vol. 3 (1) , 21
Open AccessDeveloping and evaluating stereotactic lung RT trials: what we should know about the influence of inhomogeneity corrections on dose
To investigate the influence of inhomogeneity corrections on stereotactic treatment plans for non-small cell lung cancer and determine the dose delivered to the PTV and OARs. For 26 patients with stage-I NSCLC treatment plans were optimized with unit density (UD), an equivalent pathlength algorithm (EPL), and a collapsed-cone (CC) algorithm, prescribing 60 Gy to the PTV. After optimization the first two plans were recalculated with the more accurate CC algorithm. Dose parameters were compared for the three different optimized plans. Dose to the target and OARs was evaluated for the recalculated plans and compared with the planned values. For the CC algorithm dose constraints for the ratio of the 50% isodose volume and the PTV, and the V20 Gy are harder to fulfill. After recalculation of the UD and EPL plans large variations in the dose to the PTV were observed. For the unit density plans, the dose to the PTV varied from 42.1 to 63.4 Gy for individual patients. The EPL plans all overestimated the PTV dose (average 48.0 Gy). For the lungs, the recalculated V20 Gy was highly correlated to the planned value, and was 12% higher for the UD plans (R2 = 0.99), and 15% lower for the EPL plans (R2 = 0.96). Inhomogeneity corrections have a large influence on the dose delivered to the PTV and OARs for SBRT of lung tumors. A simple rescaling of the dose to the PTV is not possible, implicating that accurate dose calculations are necessary for these treatment plans in order to prevent large discrepancies between planned and actually delivered doses to individual patients.
- 1 January 2008
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 86 (1) , 55-60
Dose calculations accounting for breathing motion in stereotactic lung radiotherapy based on 4D-CT and the internal target volume
- 1 January 2008
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 86 (1) , 55-60
Dose calculations accounting for breathing motion in stereotactic lung radiotherapy based on 4D-CT and the internal target volume